Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045493 | 0.89 | SCD (0.62) | SCDMAPTCHRM4PPARDPPARA | |
| SCHEMBL3049229 | 0.87 | SCD (0.77) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3038884 | 0.87 | SCD (1.00) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3045700 | 0.85 | SCD (0.84) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3046049 | 0.85 | SCD (0.74) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3041035 | 0.83 | SCD (0.81) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3045033 | 0.83 | SCD (0.70) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3045031 | 0.83 | SCD (0.70) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3035061 | 0.82 | SCD (0.69) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3035058 | 0.82 | SCD (0.69) | SCDHPGDNPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086970-B1 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8314138-B2 | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2086970-A2 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008024390-A2 | 2- (PYRAZIN-2-YL) -THIAZOLE AND 2- (1H-PYRAZ0L-3-YL) -THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239520-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885HPGD 344/4885NPC1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.